The data in Fig. 3B indicated that the proportion of CD4+IL-17+ Th17 cells was significantly higher in the HCC groups of early-stage (I–II) patients with various tumor sizes than in the control group; moreover, the proportion of CD4+IL-17+ Th17 cells was significantly higher in the HCC group of patients with large tumors than in the HCC group of patients with small tumors. This evidence concerns the gene IL17A and neoplasm.